Katie Murray
Adult Health · Independence, MONPI 1104139781
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,112 and has fallen 82.4% since, to $196 in 2025.
Across 144 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$531
- Boehringer Ingelheim$342
- Amgen$305
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$242
- Abbott$202
- Sanofi-aventis U.S. LLC$120
- plus $571 from 13 others
Across 11 payments — averaging $5170.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urogen Pharma, Inc.$57K
What the payments were for
- Food & beverage$2,311100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 39 | $531 |
| Boehringer Ingelheim | 20 | $342 |
| Amgen | 20 | $305 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $242 |
| Abbott | 6 | $202 |
| Sanofi-aventis U.S. LLC | 7 | $120 |
| E.r. Squibb & Sons, L.L.C. | 7 | $113 |
| Novartis | 7 | $100 |
| AstraZeneca | 5 | $79 |
| Lemaitre Vascular, Inc. | 1 | $43 |
| Baxter Healthcare | 1 | $41 |
| Amarin Pharma, Inc. | 2 | $39 |
| Novo Nordisk | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Cvrx, Inc. | 2 | $14 |
How this compares
$2,311 in reported general payments places this provider in the 75th percentile of 555 adult health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $118,570 |
| XareltoRivaroxaban | 29 | $34,411 |
| JardianceEmpagliflozin | 28 | $25,649 |
| Repatha SureclickEvolocumab | 15 | $18,499 |
| EntrestoSacubitril/Valsartan | 14 | $17,205 |
| Atorvastatin Calcium | 219 | $2,430 |
| Ezetimibe | 85 | $1,793 |
| Ranolazine ErRanolazine | 23 | $1,731 |
| Metoprolol Succinate | 102 | $1,319 |
| Rosuvastatin Calcium | 76 | $1,103 |
| ClopidogrelClopidogrel Bisulfate | 91 | $929 |
| Losartan Potassium | 125 | $803 |
| Flecainide Acetate | 15 | $710 |
| Lisinopril | 68 | $367 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 31 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $531 | $34,41129 claims |
| Boehringer IngelheimJardiance | $342 | $25,64928 claims |
| NovartisEntresto | $100 | $17,20514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 555 adult health providers in Missouri.
Other adult health in Independence
- Tabitha StithChesterfield$300K
- Stephanie VogelSaint Louis$115K
- Racquel FrisellaChesterfield$110K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Patrick BehnkeChesterfield$54K
- Elaine ZobristFenton$38K
- Yolanda Thompson MartinKansas City$32K
- Jennifer SpeiserSaint Louis$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.